Inogen (INGN) Q4 2025 earnings summary

Executive summary

• Achieved $82M in Q4 and $349M in FY2025 revenue, up 3.9–4% year-over-year, driven by strong international sales and meeting growth targets.

• Strategic transformation from a single-product company to a diversified respiratory care platform, launching new products and digital health initiatives.

• Net loss for FY2025 improved to $22.7M (down 36.6%), with positive adjusted EBITDA of $2.7M, the first since 2021.

• Board authorized a $30M share repurchase program for 2026–2027, ending 2025 with $120.9M in cash and no debt.

• International business delivered $32.5M in Q4 revenue, up 14.8–15% year-over-year, with strong execution in HME relationships and tenders.

Financial highlights

• Q4 2025 revenue: $81.7M (+2% year-over-year); FY2025 revenue: $348.7M (+3.9–4%).

• International POC sales grew 18.4% year-over-year; U.S. sales declined 3.1% for FY2025 and 5.1% in Q4.

• Rental revenue in Q4: $32.5M (+14.8%); U.S. rental revenue: $13.1M (-4.5%).

• FY2025 gross margin: 44.2% (down from 46.1%); Q4 gross margin: 43.1% (down from 45.3%).

• FY2025 adjusted net loss: $8M (improved 60.6%); Q4 adjusted net loss: $4M (improved from $5.8M).

• FY2025 positive adjusted EBITDA: $2.7M, up from negative $9.5M in 2024.

• Cash, equivalents, and securities: $120.9M, no debt.

Outlook and guidance

• FY2026 revenue guidance: $366M–$373M, ~6% year-over-year growth at midpoint.

• Expect continued positive adjusted EBITDA in 2026, with stronger growth in H2 due to new product launches and POC demand.

• Committed to launching at least one new product per year, with new launches expected to be gross margin accretive.

• Long-term goals: high single-digit revenue growth and 10%+ adjusted EBITDA margin within 3–5 years.